Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- aRigen Licenses Herpes Treatment ARYS-01 to Centaur of India
August 16, 2010
- Shionogi Obtains Approval for CUVPOSA from US FDA
August 16, 2010
- Asahi Kasei Medical Launches New Cell Culture Fluid Filter
August 16, 2010
- Kissei: Pharmaceutical Sales Up 5.9%
August 16, 2010
- Daiichi Sankyo Begins Tender Offer to Acquire Zenotech
August 16, 2010
- PMDA to Directly Investigate Deaths Reported by Med Institutions
August 16, 2010
- Forteo Offers “Aggressive”Treatment for Osteoporosis: Dr Sowa
August 16, 2010
- Nippon Shinyaku: Cialis Props Up Business
August 16, 2010
- Daiichi Sankyo Settles Lawsuit over Evoxac Patent with Apotex
August 16, 2010
- Japan PASS Interim Results for ADVATE Presented
August 16, 2010
- Takeda: Sales, Profits Down due to Lansoprazole Patent Expiration
August 16, 2010
- Fuso: Net Loss despite Increases in Sales
August 16, 2010
- Flu Vaccine Suppliers to Buy Back Med Institutions' Stocks at Their Expense
August 16, 2010
- 2,746 Welfare Recipients Receive Psychotropics from Multiple Med Institutions
August 16, 2010
- Daiichi Sankyo: Olmetec Drives Business
August 16, 2010
- Zeria: Overseas Sales Ratio Up to 13.2% with Addition of Tillotts
August 16, 2010
- AnGes MG Obtains Patent for HFG Gene Therapy for PD in the US
August 16, 2010
- JGA Fails to Achieve No-Shortage Goal in FY2009
August 16, 2010
- Astellas: Patent Expiration Hits Business
August 16, 2010
- ASKA: Seltouch Boosts Sales
August 16, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…